Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority study of low-dose cytarabine priming plus hydroxyurea versus low-dose cytarabine alone in elderly AML
TCTR20201014003Unknown
- Sponsor
- Siriraj Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of cytarabine and hydroxyurea in acute myeloid leukemia (AML) (2 arms), sponsored by Siriraj Hospital. Primary endpoint: Efficacy non-inferiority. Status: unknown.
02
Drugs
cytarabinehydroxyurea
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on TCTR20201014003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201014003.